Compare Stocks: ACRS, GMTX, VCYT, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.06 -1.8%	$5.80	$1.74 ▼ $6.60	$862.72M	0.79	1.48 million shs	3.06 million shs
CLDX Celldex Therapeutics	$39.12 -1.4%	$39.15	$22.10 ▼ $45.14	$3.12B	0.84	683,778 shs	834,300 shs
GMTX Gemini Therapeutics	$79.23 -0.2%	$77.83	$1.16 ▼ $14.10	$3.43B	-0.12	189,291 shs	204,857 shs
VCYT Veracyte	$42.45 -0.2%	$49.96	$29.45 ▼ $60.91	$3.42B	1.93	1.20 million shs	962,000 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+1.98%	+4.40%	+43.49%	+193.81%
CLDX Celldex Therapeutics	0.00%	+0.13%	-4.87%	+34.05%	+73.50%
GMTX Gemini Therapeutics	0.00%	-1.00%	+2.31%	+20.41%	+30.40%
VCYT Veracyte	0.00%	-1.53%	-9.93%	-13.63%	+31.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.06 -1.8%	$5.80	$1.74 ▼ $6.60	$862.72M	0.79	1.48 million shs	3.06 million shs
CLDX Celldex Therapeutics	$39.12 -1.4%	$39.15	$22.10 ▼ $45.14	$3.12B	0.84	683,778 shs	834,300 shs
GMTX Gemini Therapeutics	$79.23 -0.2%	$77.83	$1.16 ▼ $14.10	$3.43B	-0.12	189,291 shs	204,857 shs
VCYT Veracyte	$42.45 -0.2%	$49.96	$29.45 ▼ $60.91	$3.42B	1.93	1.20 million shs	962,000 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+1.98%	+4.40%	+43.49%	+193.81%
CLDX Celldex Therapeutics	0.00%	+0.13%	-4.87%	+34.05%	+73.50%
GMTX Gemini Therapeutics	0.00%	-1.00%	+2.31%	+20.41%	+30.40%
VCYT Veracyte	0.00%	-1.53%	-9.93%	-13.63%	+31.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	87.02% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	43.36% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
VCYT Veracyte	2.82	Moderate Buy	$54.33	27.99% Upside

Current Analyst Ratings Breakdown

Latest ACRS, GMTX, VCYT, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00
8/3/2026	VCYT Veracyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$60.00 ➝ $50.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$8.22M	103.09	N/A	N/A	$0.85 per share	7.13
CLDX Celldex Therapeutics	$1.54M	1,994.87	N/A	N/A	$7.93 per share	4.93
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
VCYT Veracyte	$561.90M	6.07	$1.49 per share	28.55	$16.57 per share	2.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
VCYT Veracyte	$66.35M	$1.41	30.11	27.56	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest ACRS, GMTX, VCYT, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
CLDX Celldex Therapeutics	N/A	11.82	11.82
GMTX Gemini Therapeutics	N/A	71.49	71.49
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CLDX Celldex Therapeutics	N/A
GMTX Gemini Therapeutics	75.42%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CLDX Celldex Therapeutics	5.20%
GMTX Gemini Therapeutics	12.90%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

ACRS, GMTX, VCYT, and CLDX Headlines

Recent News About These Companies

Insider Selling: Veracyte (NASDAQ:VCYT) Insider Sells $564,385.50 in Stock

September 7 at 4:22 AM | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Stock Price Down 4.5% After Insider Selling

September 6 at 1:21 AM | americanbankingnews.com

Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares

September 5 at 7:22 AM | insidertrades.com

Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock

September 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) CFO Sells 3,652 Shares

September 4, 2026 | marketbeat.com

Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Down 4.5% After Insider Selling

September 4, 2026 | marketbeat.com

Muna Bhanji Sells 1,864 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4, 2026 | insidertrades.com

Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells 1,864 Shares of Stock

September 3, 2026 | marketbeat.com

22,291 Shares in Veracyte, Inc. $VCYT Acquired by Man Group plc

September 3, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Purchases New Stake in Veracyte, Inc. $VCYT

September 3, 2026 | marketbeat.com

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026 | globenewswire.com

Veracyte, Inc. $VCYT Shares Sold by Moore Capital Management LP

September 1, 2026 | marketbeat.com

Wellington Management Group LLP Lowers Position in Veracyte, Inc. $VCYT

September 1, 2026 | marketbeat.com

161,973 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LP

August 31, 2026 | marketbeat.com

Alyeska Investment Group L.P. Lowers Stock Position in Veracyte, Inc. $VCYT

August 31, 2026 | marketbeat.com

269,806 Shares in Veracyte, Inc. $VCYT Purchased by Jupiter Topco LLC

August 30, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT

August 30, 2026 | marketbeat.com

437,604 Shares in Veracyte, Inc. $VCYT Purchased by Bank of New York Mellon Corp

August 30, 2026 | marketbeat.com

Legal & General Group Plc Invests $50.40 Million in Veracyte, Inc. $VCYT

August 29, 2026 | marketbeat.com

Formula Growth Ltd. Purchases Shares of 27,000 Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, GMTX, VCYT, and CLDX Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.06 -0.11 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$6.06 +0.01 (+0.08%)

As of 07:30 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Celldex Therapeutics NASDAQ:CLDX

$39.12 -0.56 (-1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$39.75 +0.63 (+1.61%)

As of 07:40 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Gemini Therapeutics NASDAQ:GMTX

$79.23 -0.14 (-0.18%)

As of 09/4/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Veracyte NASDAQ:VCYT

$42.45 -0.08 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$43.45 +1.00 (+2.36%)

As of 07:30 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRS, GMTX, VCYT, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRS, GMTX, VCYT, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRS, GMTX, VCYT, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, GMTX, VCYT, and CLDX Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Celldex Therapeutics NASDAQ:CLDX

Gemini Therapeutics NASDAQ:GMTX

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRS, GMTX, VCYT, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRS, GMTX, VCYT, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRS, GMTX, VCYT, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, GMTX, VCYT, and CLDX Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Celldex Therapeutics NASDAQ:CLDX

Gemini Therapeutics NASDAQ:GMTX

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools